DBV Systems Announces Appointment of Timothy E. Morris to Board of Administrators
4 min readGet inside of Wall Road with StreetInsider Top quality. Declare your 1-week no cost demo right here.
Montrouge, France, April 2, 2021
DBV Systems Announces Appointment of Timothy E. Morris to Board of Directors
DBV Systems (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Inventory Industry: DBVT), a clinical-phase biopharmaceutical company, introduced today the provisional appointment of Mr. Timothy E. Morris, as director, by the DBV Board of Administrators, powerful March 30, 2021. Mr. Morris will serve as a member of the Audit Committee of the Board. With this addition, the Board contains nine directors.
“We are pleased to welcome Tim Morris as a new director to the DBV Board,” said Michel de Rosen, Chairman of DBV Technologies’ Board of Directors. “Tim delivers to DBV much more than 20 a long time of leadership working experience in the biopharma sector and he is very regarded for his finance and commercial capabilities. We believe he will insert tremendous price to our Board and DBV as a complete.”
Mr. Morris has been the Chief Functioning Officer and Main Economical Officer of Humanigen, Inc. considering the fact that August 2020. Prior to becoming a member of Humanigen’s administration team, Mr. Morris served as Chair of the Company’s Audit Committee. Mr. Morris has put in far more than two many years primary the money, professional, and production capabilities at a number of public biopharmaceutical providers, like Iovance, AcelRx, VIVUS, and Questcor (previously Ribogene). Mr. Morris received his Bachelor of Science in Organization with an emphasis in Accounting from California Condition University, Chico, and is a Accredited Public Accountant (Inactive).
“The latest condition of DBV’s European and U.S. regulatory development and pipeline prospective make it an fascinating time to be part of the company,” said Timothy Morris. “I am honored to sign up for DBV and seem forward to serving as a member of the Board and Audit Committee and contributing to the results of the Enterprise.”
Mr. Morris’ appointment is topic to ratification and will be submitted to a shareholder vote at the Standard and Amazing Basic Conference that DBV Technologies will convene on May perhaps 19, 2021.
About DBV Technologies
DBV Technologies is acquiring Viaskin™, an investigational proprietary technological know-how system with wide likely apps in immunotherapy. Viaskin is based mostly on epicutaneous immunotherapy, or EPIT™, DBV Technologies’ process of delivering biologically active compounds to the immune system by intact pores and skin. With this new course of non-invasive product candidates, the Company is devoted to safely and securely reworking the care of meals allergic sufferers. DBV Technologies’ meals allergic reactions plans incorporate ongoing clinical trials of Viaskin Peanut. DBV Systems has world headquarters in Montrouge, France and places of work in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on phase B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), component of the SBF120 index, and the Company’s ADSs (every symbolizing one particular-fifty percent of just one standard share) are traded on the Nasdaq World-wide Choose Current market (Ticker: DBVT).
Ahead-Searching Statements
This press launch may possibly have ahead-wanting statements, such as statements regarding Company’s expected Regular and Amazing Standard Assembly of Shareholders, DBV’s regulatory development, and the prospective of DBV’s pipeline. These forward-searching statements and estimates are not claims or guarantees and include substantial risks and uncertainties. Between the factors that could result in true occurrences to vary materially from all those explained or projected herein include uncertainties affiliated commonly with analysis and progress, clinical trials and connected regulatory assessments and approvals and people connected with scheduling and keeping community gatherings, which include the impression of the COVID-19 pandemic A even more dialogue of challenges and uncertainties that could induce genuine results to differ materially from those set forth in the ahead-looking statements in this push release can be observed in DBV Technologies’ regulatory filings with the French Autorité des Marchés Financiers, DBV Technologies’ filings and stories with the U.S. Securities and Exchange Commission, together with in DBV Technologies’ Annual Report on Sort 10-K for the yr ended December 31, 2020, and upcoming filings and studies by DBV Systems. Present and possible traders are cautioned not to put undue reliance on these forward-seeking statements and estimates, which converse only as of the day hereof. Other than as required by applicable regulation, DBV Systems undertakes no obligation to update or revise the facts contained in this Press Release.
Investor Call
Anne Pollak
DBV Systems
+1 857-529-2363
[email protected]
Media Speak to
Angela Marcucci
DBV Technologies
+1 646-842-2393
[email protected]
